SCHEMBL620266

SCHEMBL620266

O=C1CC2(CCC2)Sc2ccccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.40
KDM4E B2RXH2 3/20 0.40
HPGD P15428 3/20 0.40
POLB P06746 3/20 0.38
HSD17B10 Q99714 3/20 0.38
GAA P10253 2/20 0.38
HTT P42858 2/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 2/20 0.35
MAPK1 P28482 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
KDM4C Q9H3R0 1/20 0.35
MEN1 O00255 4/20 0.34
KMT2A Q03164 4/20 0.34
BLM P54132 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CYP2A6 P11509 1/20 0.32
MAOA P21397 1/20 0.32
MAOB P27338 1/20 0.32
PABPC1 P11940 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12695178 0.95 ALDH1A1 (0.39) ALDH1A1KDM4EHPGDPOLBHSD17B10
SCHEMBL12481820 0.85 ALDH1A1 (0.37) ALDH1A1KDM4EHPGDPOLBHSD17B10
Hydrochloric Acid SCHEMBL3492537 0.83 ALDH1A1 (0.36) ALDH1A1KDM4EHPGDPOLBHSD17B10
SCHEMBL8812960 0.83 HTR2A (0.34) ALDH1A1KDM4EHPGDPOLBHSD17B10
SCHEMBL12836259 0.82 SIGMAR1 (0.43) ALDH1A1KDM4EHPGDPOLBHSD17B10
SCHEMBL12482094 0.80 ALDH1A1 (0.38) ALDH1A1KDM4EHPGDPOLBHSD17B10
SCHEMBL9963318 0.79 CYP2D6 (0.42) ALDH1A1KDM4EHPGDPOLBHSD17B10
SCHEMBL471434 0.77 CRBN (0.47) ALDH1A1HPGDPOLBHSD17B10LMNA
SCHEMBL6592274 0.74 ALDH1A1 (0.46) ALDH1A1KDM4EHPGDPOLBHSD17B10
SCHEMBL3493358 0.73 HDAC1 (0.42) POLBATMALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1931681-B1 SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS GLENMARK PHARMACEUTICALS SA (CH) 2012-11-14 EP disclosed
US-20120277259-A1 SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS GLENMARK PHARMACEUTICALS S.A. (CH) 2012-11-01 US disclosed
US-20120041011-A1 SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS GLENMARK PHARMACEUTICALS S.A. (CH) 2012-02-16 US disclosed
US-20110021549-A1 SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS GLENMARK PHARMACEUTICALS S.A. (CH) 2011-01-27 US disclosed
US-7842703-B2 Substituted benzofused derivatives and their use as vanilloid receptor ligands GLENMARK PHARMACEUTICALS S.A. (CH) 2010-11-30 US disclosed
US-20080269253-A1 Substituted Benzofused Derivatives and Their Use as Vanilloid Receptor Ligands GLENMARK PHARMACEUTICALS, S.A. (CH) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269253-A1 Substituted Benzofused Derivatives and Their Use as Vanilloid Receptor Ligands TRPV1, GPR17, TRPV6 ALDH1A1 665/4885KDM4E 2842/4885HPGD 401/4885
US-20120041011-A1 SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS TRPV1, GPR17, TRPV6 ALDH1A1 604/4885KDM4E 2871/4885HPGD 333/4885
US-20110021549-A1 SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS TRPV1, GPR17, TRPV6 ALDH1A1 604/4885KDM4E 2871/4885HPGD 333/4885
US-20120277259-A1 SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS TRPV1, GPR17, TRPV6 ALDH1A1 665/4885KDM4E 2842/4885HPGD 401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.